(AKTX) Akari Therapeutics - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US00972G1085
AKTX: Autoimmune, Inflammatory, Complement, Therapies, Inhibitors
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, specializes in developing innovative therapies for autoimmune and inflammatory diseases. Its lead product candidate, nomacopan, is a second-generation complement inhibitor designed to target both C5 and LTB4, addressing inflammatory and prothrombotic activities with a dual mechanism of action. The company is also advancing PASylated-nomacopan, a next-generation variant in preclinical development for geographic atrophy secondary to dry age-related macular degeneration, offering potential benefits in stability and half-life. Additionally, Akari is conducting a Phase 3 trial for hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA) in pediatric patients, leveraging nomacopans unique mechanism to address this severe and often fatal condition.
Ticker Symbol: AKTX is listed on the NASDAQ exchange, representing common stock in the Pharmaceuticals sector. The company is headquartered in Boston, Massachusetts, and can be found online at https://www.akaritx.com.
3-Month Forecast: Based on the provided data, AKTX may face resistance at the SMA 20 level of 1.01. If the stock fails to break above this level, it could continue its downward trend, potentially testing lower support levels. The relatively low ATR of 0.12 suggests limited volatility, which may result in a narrow trading range. On the fundamental side, the high P/B ratio of 3.07 indicates that the market expects significant growth, though this may be tempered by the small market capitalization of 30.35M USD. The RoE of 291.66 suggests high efficiency in generating profits with equity, which could attract investors despite the current price trends.
Additional Sources for AKTX Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
AKTX Stock Overview
Market Cap in USD | 30m |
Sector | Healthcare |
Industry | Biotechnology |
GiC Sub-Industry | Pharmaceuticals |
IPO / Inception | 2015-09-21 |
AKTX Stock Ratings
Growth 5y | -86.1% |
Fundamental | 7.84% |
Dividend | 0.0% |
Rel. Strength Industry | -47.5 |
Analysts | 5/5 |
Fair Price Momentum | 0.60 USD |
Fair Price DCF | - |
AKTX Dividends
No Dividends PaidAKTX Growth Ratios
Growth Correlation 3m | -34.6% |
Growth Correlation 12m | -42.6% |
Growth Correlation 5y | -93.8% |
CAGR 5y | -44.83% |
CAGR/Max DD 5y | -0.45 |
Sharpe Ratio 12m | -0.93 |
Alpha | -53.95 |
Beta | 0.41 |
Volatility | 81.51% |
Current Volume | 10.2k |
Average Volume 20d | 17.5k |
As of March 15, 2025, the stock is trading at USD 1.08 with a total of 10,176 shares traded.
Over the past week, the price has changed by +16.76%, over one month by +0.00%, over three months by +9.31% and over the past year by -47.06%.
Neither. Based on ValueRay Fundamental Analyses, Akari Therapeutics is currently (March 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 7.84 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of AKTX as of March 2025 is 0.60. This means that AKTX is currently overvalued and has a potential downside of -44.44%.
Akari Therapeutics has received a consensus analysts rating of 5.00. Therefor, it is recommend to buy AKTX.
- Strong Buy: 1
- Buy: 0
- Hold: 0
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, AKTX Akari Therapeutics will be worth about 0.7 in March 2026. The stock is currently trading at 1.08. This means that the stock has a potential downside of -38.89%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 80 | 7307.4% |
Analysts Target Price | 55 | 4992.6% |
ValueRay Target Price | 0.7 | -38.9% |